Evotec (EVTCY) Getting Negative Press Coverage, InfoTrie Reports
Press coverage about Evotec (OTCMKTS:EVTCY) has been trending negative recently, according to InfoTrie. The research group ranks the sentiment of media coverage by analyzing more than 6,000 news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evotec earned a news impact score of -2.11 on their scale. InfoTrie also gave media stories about the company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Evotec’s analysis:
- Evotec 9-month Profit Surges; Names Craig Johnstone As New COO – Quick Facts (nasdaq.com)
- Evotec AG (ETR:EVT): What Are The Future Prospects? (finance.yahoo.com)
- Is Evotec AG’s (ETR:EVT) CEO Paid Enough To Stay Motivated? (finance.yahoo.com)
- Evotec (EVTCY) to Release Quarterly Earnings on Tuesday (americanbankingnews.com)
- Evotec (EVTCY) Receiving Extremely Critical Media Coverage, Study Finds (americanbankingnews.com)
Shares of OTCMKTS EVTCY opened at $43.05 on Wednesday. Evotec has a twelve month low of $27.32 and a twelve month high of $52.50. The company has a market capitalization of $3.16 billion, a P/E ratio of 119.58 and a beta of 0.69. The company has a quick ratio of 0.90, a current ratio of 0.93 and a debt-to-equity ratio of 0.07.
ILLEGAL ACTIVITY WARNING: “Evotec (EVTCY) Getting Negative Press Coverage, InfoTrie Reports” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/11/14/evotec-evtcy-getting-negative-press-coverage-infotrie-reports.html.
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services.
Recommended Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.